^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MEDI6469

    i
    Other names: MEDI-6469, MEDI 6469, MEDI6469
    Associations

    News

    Trials
    Company:
    AgonOx, AstraZeneca, Providence Cancer Center
    Drug class:
    OX40 agonist
    Related drugs:
    Associations

    News

    Trials
    9ms
    Anti-OX40 Antibody in Head and Neck Cancer Patients (clinicaltrials.gov)
    P1, N=17, Completed, Providence Health & Services | Active, not recruiting --> Completed
    Trial completion
    |
    MEDI6469
    11ms
    Anti-OX40 Antibody in Head and Neck Cancer Patients (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, Providence Health & Services
    Trial completion date • Metastases
    |
    MEDI6469
    over2years
    Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=4, Terminated, Providence Health & Services | PI left the institution shortly afterwards and the study will not be re-activated. Only 4 patients were enrolled.
    Trial termination • Combination therapy • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD38 (CD38 Molecule) • CD4 (CD4 Molecule)
    |
    MEDI6469
    over3years
    Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells. (PubMed, Nat Commun)
    These data provide evidence that anti-OX40 prior to surgery is safe and can increase activation and proliferation of CD4+ and CD8+ T cells in blood and tumor. Our work suggests that increases in the tumor-reactive CD103+ CD39+ CD8+ TIL could serve as a potential biomarker of anti-OX40 clinical activity.
    Clinical • Clinical Trial,Phase I • Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    |
    MEDI6469